Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 157 Plus Cat Immunotherapy for Cat Allergy
NCT02237196Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2015
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tezepelumab in cat allergy, sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2015; status: completed.
02
Drugs
03
Conditions
cat allergy
Beyond the preview
Go deeper on NCT02237196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02237196.